China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million (USD 14.6 million) in a Series C+ financing round. The funding was backed by Guoyao Zhongjin (Shanghai) Medical Health Investment, ZhangKeHeRun Fund, Lingang Lanwan Private Equity Fund, and SPINNOTEC/Haiwang Capital. With this latest round, ZhenGe Biotech has amassed a total of USD 325 million to date.
Funding Details
The Series C+ financing round for ZhenGe Biotech, a leading CDMO in China, has received significant support from prominent investors. The funds will be utilized to further expand the company’s operations and enhance its capabilities in the biopharmaceutical manufacturing sector.
Company Overview and Facilities
Founded in 2017 in the Lingang Special Area of Shanghai, ZhenGe Biotech has established a robust presence in the biopharmaceutical industry. The company boasts a 66,000 square-meter Good Manufacturing Practice (GMP) commercial production base and R&D center in Lingang. The Phase I of the facility is nearing completion, featuring three 2,000-liter disposable reactor lines and three 5,000-liter stainless steel reactor lines.-Fineline Info & Tech
